NCT00739453 2024-11-20A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)Astellas Pharma IncPhase 1 Completed95 enrolled
NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT00030498 2013-01-16Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney DysfunctionNational Cancer Institute (NCI)Phase 1 Completed75 enrolled